65,437 trials
Gaucher Disease
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAE) Following Initiation of Treatment With Velaglucerase Alfa — 41; 27 Participants
Diabetes · Hyperglycemia
Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
Hip Osteoarthritis · Knee Osteoarthritis · Hip Arthroplasty
Primary: Berg Balance Scale — 53; 52.4 Score on a scale
Mental Health Issue · Alcohol Use Disorder · Depression
Primary: Proportion of Participants Who Schedule Professional Treatment — 8 Participants
Ovarian Neoplasms
Primary: Efficacy: Progression Free Survival (PFS) — 3.1; 5.6; 3.8 months — p=0.265
Polycystic Ovary Syndrome (PCOS)
Primary: Lipid Content of PCOS Subcutaneous (SC) Abdominal Adipocytes Matured in Vitro. — 2.0; 5.6; 1.37; 3.8 fluorescence units/cell number — p=0.004
Human Immunodeficiency Virus · Hepatitis C · Alcohol Abuse
Primary: Percentage of Women Who Test Ethyl Glucuronide (EtG) Negative — 93; 99 Participants
Depression · HIV
Primary: Change in Patient Health Questionnaire (PHQ)-9 — 5; 7 units on a scale
Carcinoma, Non-Small-Cell Lung
Primary: Objective Response Rate Using RECIST v1.1 to Nivolumab and Ipilimumab When Administered in Combination to Patients With Pre-treated Advanced NSCLC Who Have Experienced…
Substance Use Disorders
Primary: Examine Feasibility (Eligible Participant Recruitment) — 45; 55 Participants
Classical Hodgkin Lymphoma
Primary: PART A: Number of Participants Who Complete of 2 Cycles of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) — 30 Participants
Breast Cancer
Primary: Area Under the Curve for Cancer Detection Rates of CESM Compared With Breast MRI for Breast Cancer Screening — 0.91; .91 Probability of malignancy
Cardiac Disease
Primary: mPAP-to-MAP Ratio — 0.394; 0.385; 0.42; 0.40 ratio of mPAP-to-MAP — p=0.53
Mydriasis
Primary: Mean Change in Pupil Diameter From Baseline — 4.55; 4.88 millimeters
Insomnia
Primary: Number of Participants With Major Depressive Disorder — 37; 62 Participants